new opportunities?

The more I think of this, the more likely it seems to me that the company will come up with some kind of new direction either using it's oral fluid testing IP, or some other acquisition or a combination of the two.

Howard Digby is involved with Forrest Capital who I believe were the ones behind the following successful biotech acquisitions/transactions which all resulted in significant re-rates:

Cynata Therapeutics / EchoQuest (ECQ, now CYP)
Oncosil / Neurodiscovery (NDL, now OSL)
Imugene (IMU)

SBN also still share two board members with Cynata.


Forrest Capital:
http://www.forrestcapital.com.au/directors--consultants.html


Taken from SBNs latest quarterly:

"The Company also continues to consider licensing and acquisition of biotechnology opportunities in the broader space.....

7. Commence development on new products, some in conjunction with partners. "


Taken from 24th Jan annc:

"The company is commercialising new improved versions of its “Oraline®” hand held multi drug test device while also looking to increase its biotechnology investments."


Taken from today's annc:

"In addition, LumiQuick’s presence in disease diagnostics provides Sun Biomedical with future opportunities in the healthcare sector.” "

So although work on the new and improved version of Oraline IV seems to be progressing well, I reckon that real value will come from an acquisition/transaction, hopefully aligned with their existing oral fluid testing - perhaps oral fluid testing designed to test disease as well as drug abuse.